We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

2 hedge funds and large institutions have $0 invested in Navidea Biopharmaceuticals Inc. in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

100% less capital invested

Capital invested by funds: $13 → $0 (-$13)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

NAVB Hedge Fund Activity: Q2 2024 in Review

2 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2024, worth a combined $0 — down 100% from $13 a quarter earlier.

Fund positioning in NAVB was balanced in Q2 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $0 of Navidea Biopharmaceuticals Inc. stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2024 and 0 closed out.

Based on aggregated 13F filings for Q2 2024.